Bio-Rad Laboratories (NYSE:BIO) executives said the company finished 2025 within revised guidance for revenue and operating ...
21h
Bio-Rad Laboratories Inc (BIO) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges
Bio-Rad Laboratories Inc (BIO) reports a 3.9% sales increase in Q4 2025, driven by diagnostics growth, despite supply chain and market headwinds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results